A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia

Authors :: Andrea Mannucci
Adnan Nagrial
Catello Somma
Jason D. Lickliter
Jianjun Zou
Mark Voskoboynik
Michael Millward
Tarek Meniawy
Lianshan Zhang
Katherine Woods
Peter Grimison
Michael Lahn
Surein Arulananda
Hui K Gan
Pablo Fernandez-Penas
Andreas Behren
Bo Gao
Michelle Harrison
Howard Kallender
Stacey Luo
Source :: Drug Design, Development and Therapy. 14:1177-1189
Publication Year :: 2020
Publisher :: Informa UK Limited, 2020.
Abstract: Purpose Camrelizumab inhibits PD-1 in non-clinical models and showed typical non-clinical pharmacokinetic (PK) and safety profiles for an IgG4 monoclonal antibody. We report results from the First-in-Human Phase 1 trial of camrelizumab in Australian population.

Full Text Access

Tools